Acquired Hemophilia Treatment Market Report 2026

The acquired hemophilia treatment market size has grown steadily in recent years. It will grow from $12.83 billion in 2025 to $13.39 billion in 2026 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to limited availability of specialized hemophilia treatments, rising prevalence of acquired hemophilia cases, dependence on hospital-based care, increasing awareness of bleeding disorders, adoption of on-demand treatment protocols.

The acquired hemophilia treatment market size is expected to see steady growth in the next few years. It will grow to $15.91 billion in 2030 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to technological advancements in gene therapy, expansion of prophylaxis treatment adoption, growth of personalized medicine in hematology, rising investment in hemophilia research, increasing access to advanced treatment options in emerging regions. Major trends in the forecast period include rising adoption of clotting factor replacement therapies, increasing use of gene therapy for hemophilia prophylaxis, expansion of personalized treatment plans for acquired hemophilia, growing awareness and early diagnosis programs, focus on reducing bleeding episodes and inhibitor eradication.

A growing number of ongoing clinical trials is expected to drive the growth of the acquired hemophilia treatment market in the coming years. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. These trials assess the safety and efficacy of new treatments for acquired hemophilia, advancing research to improve patient outcomes and establish effective therapeutic interventions. For instance, in December 2024, data from the Association of the British Pharmaceutical Industry, a UK-based trade association, showed that the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, a growing number of ongoing clinical trials is contributing to the growth of the acquired hemophilia treatment market.

Major companies operating in the acquired hemophilia treatment market are focusing on providing drugs with enhanced features and securing regulatory approvals to maintain their market position. Drug approvals for routine prophylaxis are rising, primarily due to the need for safer and more effective therapies. For instance, in June 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based drug manufacturer, presented final analysis data from its Japanese Phase III clinical trial (AGEHA Study) on Hemlibra (emicizumab) for acquired hemophilia A at the 31st ISTH Annual Congress. The study included patients receiving immunosuppressive therapy as well as those ineligible for such therapy. Hemlibra demonstrated long-term efficacy in managing bleeding events, supporting its expanded use in individuals with acquired hemophilia A who require prompt and effective treatment.

In June 2023, Baudax Bio., a US-based pharmaceutical company, acquired TeraImmune Inc. for an undisclosed amount. Through this acquisition, Baudax Bio aimed to combine TeraImmune’s scientific expertise with Baudax’s established proficiency in executing clinical development programs and incorporate TeraImmune’s TI-168 asset into its portfolio. This asset is a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to neutralize clotting factor VIII (FVIII) inhibitors in Hemophilia A patients. TeraImmune Inc. is a US-based advanced research company developing treatments for hemophilia.

Major companies operating in the acquired hemophilia treatment market are Roche Holding AG, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Pfizer Inc., Bayer AG, CSL Limited, Grifols SA, Octapharma AG, Kedrion Biopharma Inc., Sanofi SA, Sobi Inc., Chugai Pharmaceutical Co. Ltd., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Medexus Pharmaceuticals Inc., Ferring Pharmaceuticals BV, Hema Biologics LLC, Bio Products Laboratory Ltd., LFB SA.

North America was the largest region in the acquired hemophilia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acquired hemophilia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acquired hemophilia treatment market by raising costs for imported clotting factor products, gene therapy materials, and delivery equipment. Segments such as prophylaxis treatments and on-demand clotting factor replacement are particularly affected, with regions including north america, europe, and asia-pacific experiencing increased procurement costs. These tariffs have caused supply chain delays and higher treatment expenses, but they have also encouraged local production initiatives and innovation in alternative therapies, enhancing long-term regional self-reliance.

The acquired hemophilia treatment market research report is one of a series of new reports that provides acquired hemophilia treatment market statistics, including acquired hemophilia treatment industry global market size, regional shares, competitors with a acquired hemophilia treatment market share, detailed acquired hemophilia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acquired hemophilia treatment industry. This acquired hemophilia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acquired hemophilia treatment refers to the therapeutic strategies used to manage and treat acquired hemophilia, a non-hereditary bleeding disorder caused by a mutation or alteration in a gene responsible for producing clotting factor proteins essential for blood clot formation. The treatment focuses on controlling bleeding episodes and eliminating the inhibitors that target clotting factors.

The primary approaches for acquired hemophilia treatment include on-demand therapy and prophylaxis. On-demand treatment involves administering clotting factor replacement therapy only in response to clinically significant bleeding. This approach is used for hemophilia A, hemophilia B, hemophilia C, and other types, and is provided by hospitals, clinics, and other healthcare end users.

The acquired hemophilia treatment market consists of revenues earned by entities by providing services such as eradication of inhibitors, individualized therapeutic approach, multidisciplinary approach, and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired hemophilia treatment market also includes sales of immunosuppressive agents including cyclosporine A, and azathioprine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.